Clinical Trial IDNCT00298636
Lead SponsorXsira Pharmaceuticals
Principal Investigator
  • Tong J Gan
Start Date2005-10-01
Completion Date
Study TypeInterventional
PhasePhase 2
StatusCompleted

Purpose

Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management. Activated spinal A1 receptors inhibit sensory transmission by inhibiting the slow ventral root potential, which is the C-fiber-evoked excitatory response associated with nociception. Adenosine may inhibit intrinsic neurons through an increase in K+ conductance and presynaptic inhibition of sensory nerve terminals to inhibit the release of substance P and perhaps glutamate. Although adenosine A3 receptors are not found in the nervous system, adenosine is also known to have anti-inflammatory properties that may contribute to pain relief in the peripheral setting of inflammation.

Conditions

ConditionInterventionPhase
Perioperative PainDrug: adenosinePhase 2

Eligibility

AgeGenderAccepts Healthy Volunteers
18 Years to 65 YearsFemaleNo